Significance of Uracil/Tegafur for Preventing Intravesical Recurrence of Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Current Urology, 05/25/2012Harada KI et al.
Despite the significant induction of γ–butyrolactone (GBL), adjuvant uracil/tegafur (UFT) therapy failed to show a preventive effect on intravesical recurrence of non–muscle invasive urothelial carcinoma of the bladder. Therefore, the authors should consider enhancing the anti–angiogenic effect of GBL using an alternative administration schedule of UFT.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.